For Healthcare Professionals

A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

clipboard-pencil

About the study

The purpose of this study is to investigate the effects of nivolumab when given under the skin with or without rHuPH20. This study will include participants with 1 of the following advanced or metastatic tumors approved for treatment with nivolumab monotherapy: - non-small cell lung cancer (NSCLC) - renal cell carcinoma (RCC) - unresectable or metastatic melanoma - hepatocellular carcinoma (HCC) - microsatellite instability-high or mismatch repair deficient colorectal cancer (MSI-H/dMMR CRC) - in Part B, other solid tumors may be considered at the discretion of the Clinical Trial Physician - In addition to the above tumors, Part E will also include participants with metastatic urothelial carcinoma (mUC).
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Histologic or cytologic confirmation of advanced (metastatic and/or unresectable) solid tumors of one of the following tumor types:
  2. Metastatic squamous or non-squamous NSCLC
  3. RCC, advanced or metastatic
  4. Melanoma
  5. HCC
  6. CRC, metastatic (MSI-H or dMMR)
  7. In Part B, other solid tumor types may be considered at the discretion of the Medical Monitor
  8. In Part E, Metastatic urothelial carcinoma
  9. Measurable disease as per RECIST version 1.1 criteria
  10. ECOG performance status of 0 or 1

EXCLUSION CRITERIA

  1. Active brain metastases or leptomeningeal metastases
  2. Ocular melanoma
  3. Active, known, or suspected autoimmune disease Other protocol defined inclusion/exclusion criteria apply
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 855-907-3286Email iconEmail Study Center

Study’s details


Contition

Neoplasms by Site

Age

18+

Phase

Phase 1/Phase 2

Participants needed

140

Est. Completion Date

Mar 2025

Treatment type

Interventional


Sponsor

Bristol-Myers Squibb

ClinicalTrials.gov identifier

NCT03656718

Study number

CA2098KX

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.